Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (12): 761-763.
Previous Articles Next Articles
ZHOU Qiuyun, ZHANG Yu, ZHANG Liang, LU Lei, LU Tao
Received:
2019-01-18
Revised:
2019-01-18
Online:
2018-12-20
Published:
2019-01-18
CLC Number:
ZHOU Qiuyun, ZHANG Yu, ZHANG Liang, LU Lei, LU Tao. One Case of Severe Myelosuppression and Diarrhea Induced by Irinotecan Injection in a UGT1A1*28 Wide-type Patient[J]. Chinese Journal of Pharmacovigilance, 2018, 15(12): 761-763.
[1] Zhou C F, Ma T, Su Y, et al.UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastroin-testinal cancer[J]. Anticancer Agents Med Chem, 2013, 13(2): 235-241. [2] Zhang X G, Zhang X.Study on the development of the mechanism of action, prevention and treatment for irinotecan-induced diarrhea[J]. Chinese Journal of Pharmacovigilance, 2012, 9(9): 535-538. [3] Di Paolo A, Bocci G, Polillo M,et al.Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity[J]. Curr Drug Metab, 2011, 12(10):932-943. [4] Innocenti F, Undevia S D, Iyer L, et al.Genetic variants in the UDP–glucuronosyltransferase 1A1 gene predict the risk of severe neu-tropenia of irinotecan[J]. J Clin Oncol, 2004, 22(8): 1382-1388. [5] Massacesi C, Terrazzino S, Marcucci F, et al.Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy[J]. Cancer, 2006, 106( 5): 1007-1016. [6] Liu X L, Yang M D, Gao J.Relationship between UGT1A1 gene pol-ymorphisms and toxicity of irinotecan[J]. Chin Remedies&Clin, 2013, 13( 11): 1402-1404. [7] Takahara N, Nakai Y, Isayama H, et al.Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer[J]. Cancer Chem Pharmacol, 2013, 71(1): 85-92. [8] Harada T, Saito H, Karino F, et al.Clinical usefulness of testing for UDP glucuronosyltransferase 1 family,polypeptide A1 polymorp-hism prior to the nititation of irinotecan-based chemotherapy[J]. Mol Clin Oncol, 2014, 2(5): 737-743. [9] Schulz C, Heinemann V, Schalhorn A, et al.UGT1A1 gene polymorphism Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorecatal cancer[J]. World J Gastroenterol, 2009, 15(40): 5058-5066. [10] Kehrer D, Sparreboom A, Verweijj, et al. Modualtion of irinotecan induced diarrhea by cotreatment with neomycin in cancer patients[J]. Clin Cancer Res, 2001, 7(5), 1136-1141. [11] 刘建平,邢建民. 循证的药品不良反应评价方法[J]. 中国药物警戒, 2010, 17(1): 12-15. [12] 范燕,汤韧,井春梅,等. 药学期刊药品不良反应案例报道论文的要点探讨[J].中国药物警戒, 2017, 1(2): 101-103. [13] Cheng L, Li M,Hu J, et al.UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analrsis in Asians[J]. Cancer Chemother Pharmaco, 2014, 73(3), 5551-560l. [14] Takano M, Kato M, Yoshikawa T, et al.Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination-chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study[J]. Oncology, 2009, 76(5): 315-321. [15] Han J Y, Lim H S, Sin E S, et al.Influence of the organican iontransporting polypeptide 1B1(OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advancednon-small cell lung cancer[J], Lung Cancer, 2008, 59(1): 69-75. [16] 张晓光,张侠. 25例伊立替康治疗晚期肠癌致不良反应的分析[J]. 中国药物警戒 , 2013, 10(3): 168-171. [17] Nies A T, Niemi M, burk O, et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of QATP1B3 and OATP2B1[J]. Genome Med, 2013, 5(1):1. [18] Takane H, Miyata M, Burioka N, et al.Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLO1B1*15 Allele[J]. Ther Drug Monit, 2007, 29(5): 666-668. |
[1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
[2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
[3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
[4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
[6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
[7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
[8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
[9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
[10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
[11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
[12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
[13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
[14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
[15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||